Last reviewed · How we verify
NRL972
NRL972 is a selective inhibitor of neutrophil elastase that reduces protease-mediated tissue damage in inflammatory airway diseases.
NRL972 is a selective inhibitor of neutrophil elastase that reduces protease-mediated tissue damage in inflammatory airway diseases. Used for Cystic fibrosis, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | NRL972 |
|---|---|
| Also known as | cholyl-lysyl-fluorescein |
| Sponsor | Norgine |
| Drug class | Neutrophil elastase inhibitor |
| Target | Neutrophil elastase (NE) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Neutrophil elastase is a serine protease released by activated neutrophils that contributes to excessive inflammation and tissue destruction in conditions like cystic fibrosis and COPD. By selectively inhibiting this enzyme, NRL972 aims to reduce pathological inflammation while preserving the antimicrobial functions of neutrophils. This targeted approach may help slow disease progression and improve lung function in chronic inflammatory airway conditions.
Approved indications
- Cystic fibrosis
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Respiratory tract infections
- Cough
- Gastrointestinal disturbances
Key clinical trials
- PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) (PHASE2)
- Sensitivity of Alternative NRL972 Detection Methods in Healthy Subjects (PHASE1)
- Reproducibility of Child-Turcotte-Pugh (CTP) Rating and NRL972 Pharmacokinetics in Patients With Cirrhosis (PHASE1)
- Effect of Chronic Viral Hepatitis on the Pharmacokinetics of NRL972. (PHASE2)
- Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity. (PHASE3)
- Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin (PHASE1)
- Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers (PHASE1)
- Evaluation of the Pharmacokinetics of NRL972 Following Pre-Administration of Rifampicin and Cyclosporine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NRL972 CI brief — competitive landscape report
- NRL972 updates RSS · CI watch RSS
- Norgine portfolio CI